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Abstract
While the bone morphogenetic protein-7 (BMP-7) is a well-known therapeutic 
growth factor reverting many fibrotic diseases, including peritoneal fibrosis by peri-
toneal dialysis (PD), soluble growth factors are largely limited in clinical applications 
owing to their short half-life in clinical settings. Recently, we developed a novel drug 
delivery model using protein transduction domains (PTD) overcoming limitation of 
soluble recombinant proteins, including bone morphogenetic protein-7 (BMP-7). This 
study aims at evaluating the therapeutic effects of PTD-BMP-7 consisted of PTD 
and full-length BMP-7 on epithelial-mesenchymal transition (EMT)-related fibro-
sis. Human peritoneal mesothelial cells (HPMCs) were then treated with TGF-β1 or 
TGF-β1 + PTD-BMP-7. Peritoneal dialysis (PD) catheters were inserted into Sprague-
Dawley rats, and these rats were infused intra-peritoneally with saline, peritoneal 
dialysis fluid (PDF) or PDF + PTD-BMP-7. In vitro, TGF-β1 treatment significantly 
increased fibronectin, type I collagen, α-SMA and Snail expression, while reducing 
E-cadherin expression in HPMCs (P < .001). PTD-BMP-7 treatment ameliorated TGF-
β1-induced fibronectin, type I collagen, α-SMA and Snail expression, and restored 
E-cadherin expression in HPMCs (P < .001). In vivo, the expressions of EMT-related 
molecules and the thickness of the sub-mesothelial layer were significantly increased 
in the peritoneum of rats treated with PDF, and these changes were significantly ab-
rogated by the intra-peritoneal administration of PTD-BMP-7. PTD-BMP-7 treatment 
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1  | INTRODUC TION
Peritoneal dialysis (PD) is a modality of renal replacement therapy 
using a semipermeable membrane where ultrafiltration and diffusion 
occur.1 As PD duration prolongs, prolonged exposure to bio-incom-
patible PD solutions and recurrent peritonitis causes chronic inflam-
mation and subsequent injury to the peritoneal membrane, which 
undergoes progressive fibrosis and angiogenesis, eventually leading 
to ultrafiltration loss.2
Epithelial-mesenchymal transition (EMT) of the peritoneal 
mesothelial cells (PMCs) is a key process of peritoneal fibrosis.2 
Transforming growth factor-β1 (TGF-β1) and bone morphogenetic 
protein-7 (BMP-7) are two key factors in the balance of their biolog-
ical activities in EMT of PMCs by counter-regulatory mechanism.3-5 
TGF-β1, a strong profibrotic cytokine, is known as a master molecule 
in the structural change and functional deterioration of the perito-
neal membrane.6 On the other hand, BMP-7, which is an endoge-
nous anti-fibrotic protein via the blocking activation of downstream 
Smad 2/3 cascades, restores E-cadherin expression to normal levels 
through Smad 1/5/8 up-regulation, suggesting repair of severely 
damaged PMCs.7-9 In fact, some studies showed that recombinant 
BMP-7 (rBMP-7) or adenovirus-mediated expression of BMP-7 re-
versed the TGF-β1-induced EMT and peritoneal fibrosis in in vitro 
or in vivo models.3-5 Although rBMP-7 presents as a promising 
therapeutic for many TGF-β1-dependent fibrotic diseases, there 
are several critical limitations due to soluble nature of recombinant 
proteins. For example, unlike in vitro culture dish, intra-peritoneal 
administration of soluble and bioactive rBMP-7 in vivo inevitably 
leads to their initial burst release and short half-life because of rapid 
clearance by body fluid and proteolytic degradation.10-12 Because of 
these limitations, excess dosages of rBMP-7 are often administered 
to achieve clinical effectiveness. Therefore, a high dosage of rBMP-7, 
during a long-term regeneration period (often several weeks), inevi-
tably increases the possibility of spreading to nearby tissues or blood 
circulation with many adverse effects, while remaining cost-inef-
fective. While adenovirus-mediated BMP-7 can provide long-term 
release, viral transduction for clinical therapeutics is largely limited 
because of safety concerns.
Recently, it has been found that protein transduction domain 
(PTD) peptides deliver proteins into the cell across the plasma 
membrane as a part of the physiologic process.13 In terms of ther-
apeutic benefits without raising safety concerns regarding gene 
delivery, PTD is widely investigated as carrier for therapeutic mac-
romolecules.14 The PTD-fusion polypeptide is rapidly internalized 
through lipid raft-dependent macropinocytosis after the initial ionic 
contact with the cell membrane independent of specific receptors.15 
Interestingly, the denatured polypeptides delivered into the cells 
refold into active form.16,17 Unfortunately, the mechanism detail-
ing the intracellular processing of the delivered protein is not yet 
to be fully explained.16-18 We have previously reported that PTD-
mediated transduction of BMP provides a novel drug delivery model 
overcoming limitations of current soluble recombinant proteins.12 
Therefore, this study was undertaken to evaluate the effect of PTD-
BMP-7 on TGF-β1-induced EMT in cultured human peritoneal me-
sothelial cells (HPMCs). Furthermore, the effects of PTD-BMP-7 on 
EMT and peritoneal fibrosis were investigated in peritoneal dialysis 
fluid (PDF)-induced peritoneal fibrosis animal models.
2  | MATERIAL S AND METHODS
2.1 | Ethnic statement
The study was approved by the Committee for the Care and Use of 
Laboratory Animals at Yonsei University College of Medicine (Seoul, 
Republic Korea), according to the Principles of Laboratory Animal 
Care (NIH Publication no. 85-23, revised 1985).
2.2 | Bacterial expression, production of PTD-
BMP-7, and isolation of HPMCs
The bacterial expression cassette for the PTD-fusion BMP-7 poly-
peptide and the purification procedures have been described previ-
ously.12 HPMCs were isolated in accordance with the process stated 
by Stylianou et al.19
2.3 | Transduction of PTD-BMP-7 into HPMCs
PTD-BMP-7 was directly introduced into the HPMC culture medium 
for 24 hours. Using immunofluorescence analysis, PTD-BMP-7 was 
detected via the antibodies against the BMP-7 (ab29569, Abcam). Of 
note, 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) to counter-
stain nuclei was used. Additionally, HPMCs were grown in 10% foetal 
bovine serum (FBS)-free M199 media (Sigma-Aldrich Corp). FBS-
free M199 media + 4.25% PDF (Physioneal; Baxter International, 
Deerfield, IL, USA). HPMCs were also treated with different doses 
of PTD-BMP-7 for 2 hours. The soluble and insoluble fractions of 
lysate were obtained from Triton X-100 lysis buffer. Xpress and 
significantly inhibited the progression of established PD fibrosis. These findings sug-
gest that PTD-BMP-7, as a prodrug of BMP-7, can be an effective therapeutic agent 
for peritoneal fibrosis in PD patients.
K E Y W O R D S
and peritoneal fibrosis, protein transduction domain, PTD-BMP-7
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BMP-7 protein expressions of insoluble fractions were analysed 
using Western blot analysis. To determine adequate processing of 
PTD-BMP-7 and secretion of BMP-7 in HPMCs, PTD-BMP-7 was 
transduced into the HPMCs for 2 hours, followed by sterile phos-
phate-buffered saline (PBS) washing and refreshment of FBS-free 
M199 media containing Noggin (SRP4675; Sigma-Aldrich Corp.), an 
endogenous inhibitor which binds competitively BMP-7 receptor on 
the cell membrane. After 4 hours of incubation with PTD-BMP-7, the 
culture media was harvested and subjected to BMP-7 ELISA assay kit 
(DBP700; R&D Systems) according to the manufacturer's protocol to 
evaluate secreted BMP-7.
2.4 | In vitro experiments
3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
cell viability assay kit (Thermo Fisher Scientific) was performed 
to determine the PTD-BMP-7 dose used in the experiments.20 
Subconfluent HPMCs were FBS-restricted for 24 hours after which 
the media was replaced into 1% FBS media for the control group and 
the same media with TGF-β1 (2 ng/mL) (R&D Systems) for the TGF-
β1 group. Both groups were treated with PTD-BMP-7 (100 ng/mL). 
Preliminary experiments determined the doses of TGF-β1 and PTD-
BMP-7 in this study. Cells were harvested 72 hours after treatment 
with each stimulus.
2.5 | Animal experiments
Peritoneal access ports were implanted in male Sprague-Dawley 
rats weighing 200-250 g, and 2 mL of saline containing 1 IU/mL 
of heparin was injected intra-peritoneally until the wound healed. 
First, control rats (n = 6) were instilled with a daily (once per day) 
20 mL dose of saline. The remaining rats (n = 12) were injected daily 
with 20 mL of 4.25% PDF for 4 weeks with or without PTD-BMP-7 
(50 μg/kg, weekly). The PTD-BMP-7 was mixed with PDF prior to 
intra-peritoneal administration (PDF + PTD-BMP-7). Of note, to 
evaluate the effects of PTD-BMP-7 on the prevention of peritoneal 
fibrosis based on the dosage of PTD-BMP-7, we performed the same 
procedure in the 18 male Sprague-Dawley rats. Among them, each 
three rats were instilled with 4.25% PDF + saline (20 mL/d), or dif-
ferent doses of PTD-BMP-7 (0.05, 0.5, 5, 50 and 500 μg/kg/wk) for 
4 weeks. Next, to evaluate the effects of PTD-BMP-7 on the estab-
lished PDF-induced peritoneal fibrosis, we performed the same pro-
cedure in 30 male Sprague-Dawley rats. Each of six rats was instilled 
with a daily (once per day) 20 mL dose of saline with or without PTD-
BMP-7 (50 μg/kg, weekly), and the remaining 18 rats were injected 
with 20 mL of PDF daily for 6 weeks. Among those, six rats were in-
jected with a mixture of PTD-BMP-7 (50 μg/kg, weekly) and PDF for 
6 weeks (PDF + 1-6 weeks of PTD-BMP-7), while 6 rats were treated 
with PTD-BMP-7 (50 μg/kg, weekly) after 2 weeks of PDF treatment 
(PDF + 3-6 weeks of PTD-BMP-7). Lastly, to compare the effective-
ness of PTD-BMP-7 to those of rBMP-7, we also performed the same 
procedure in 36 male Sprague-Dawley rats. Among them, each six 
rats were instilled with saline (20 mL/d), saline (20 mL/d) + PTD-
BMP-7 (50 μg/kg, weekly) and saline (20 mL/d) + rBMP-7 (50 μg/
kg, weekly). The remaining 18 rats were injected with 20 mL of PDF 
daily for 4 weeks. Among those, six rats were injected with rBMP-7 
(50 μg/kg, weekly) + PDF for 4 weeks, while 6 rats were injected 
with PTD-BMP-7 (50 μg/kg, weekly) + PDF for 4 weeks.
2.6 | Total RNA extraction and reverse transcription
The RNA extraction method from HPMCs was described in a previous 
study.21 Extracted RNA was precipitated by adding 400 µl of isopro-
panol and centrifuged at 12 000 g for 30 minutes at 4°C. The RNA 
pellet was washed with 70% ethanol, air-dried for 2 minutes and dis-
solved in sterile DEPC-treated distilled water. A Boehringer Mannheim 
cDNA synthesis kit (Boehringer Mannheim GmbH) was used to obtain 
first-strand cDNA. Reverse transcription was conducted using 2 µg 
of total RNA extracts with 10 µmol/L random hexanuclotide prim-
ers, 1 mmol/L dNTPs, 8 mmol/L MgCl2, 30 mmol/L KCl, 50 mmol/L 
Tris-HCl at pH 8.5, 0.2 mmol/L dithiothreithol, 25 U RNAse inhibitor 
and 40 U AMV reverse transcriptase. The mixture was incubated for 
10 minutes at 30°C, and then for 1 hour at 42°C, followed by incuba-
tion for 5 minutes at 99°C for the inactivation of the enzyme.
2.7 | Quantitative real-time polymerase chain 
reaction (qRT-PCR)
The primer sequences used in this study were described in Table S1. 
The RNAs used for amplification were 25 ng per reaction tube. 
Using the ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems), a total volume of 20 µL mixture in each well was 
used containing 10 µL of SYBR Green PCR Master Mix (Applied 
Biosystems), 5 µL of cDNA, and 5 pmol sense and antisense primers. 
The PCR conditions were as follows: 35 cycles of denaturation for 
30 minutes at 94.5°C, annealing for 30 seconds at 60°C and exten-
sion for 1 minutes at 72°C. Initial heating for 9 minutes at 95°C and 
final extension for 7 minutes at 72°C were performed for all PCR 
reactions. After real-time PCR, the temperature was increased from 
60 to 95°C at a rate of 2°C/min to construct a melting curve. The 
cDNA content of each specimen was determined using a compara-
tive CT method with 2
–ΔΔCT. The results were given as the relative 
expression normalized to the expression of 18S rRNA and expressed 
in arbitrary unit.
2.8 | Western blot analysis
Western blot analysis of harvested cultured cells and the mouse peri-
toneum were conducted. Harvested cultured cells and the mouse peri-
toneum were lysed in sodium dodecyl sulphate (SDS) sample buffer 
[2% SDS, 10 mmol/L Tris-HCl at pH 6.8, 10% (vol/vol) glycerol]. Lysates 
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were centrifuged at 10 000 g for 10 minutes at 4°C, and the supernatant 
was stored at −70°C. Protein concentrations were determined using 
the Bio-Rad kit (Bio-Rad Laboratories, Inc). Laemmli sample buffer was 
added to aliquots of 50 µg of the protein extracts, which were heated 
for 5 minutes at 100°C and electrophoresed in acrylamide denatur-
ating SDS-polyacrylamide gel. A Hybond-ECL membrane was used to 
transfer protein using a Hoeffer semidry blotting apparatus (Hoeffer 
Instruments). After the protein was transferred to the membrane, it 
was incubated in blocking buffer A (1X PBS, 0.1% Tween-20 and 5% 
nonfat milk) for 1 hour at room temperature, and then incubated over-
night at 4°C in a 1:500 dilution of polyclonal antibodies to Xpress (46-
0528; Invitrogen), BMP-7 (ab84684; Abcam), fibronectin (A0245; Dako, 
Glostrup, Denmark), type I collagen (1310-01; SothernBiotech), α-SMA 
(ab5694; Abcam), E-cadherin (610181; BD Bioscience), Snail (ab85936; 
Abcam), phospho-Smad 2/3 (p-Smad 2/3, 8828S; Cell Signaling 
Technology Inc), Smad 2/3 (3102S; Cell Signaling Technology Inc) or 
β-actin (A5441; Sigma Chemical Co.). The membranes were washed 
thrice for 10 minutes in 1 × PBS with 0.1% Tween-20 and incubated 
in buffer A containing a 1:1000 dilution of horseradish peroxidase-
linked goat anti-rabbit or anti-mouse IgG (Santa Cruz Biotechnology, 
Inc). The washing process was repeated thrice, and the membranes 
were developed with a chemiluminescent agent (ECL; Amersham Life 
Science, Inc). TINA image software (Raytest, Straubenhardt, Germany) 
was used to measure the band densities, and the changes in the optical 
densities of bands from the treated groups relative to control cells or 
tissues were used for analysis.
2.9 | Immunohistochemical staining and Masson's 
trichrome staining
The peritoneum samples were fixed in 10% neutral-buffered for-
malin, processed in the standard manner, and 5 µm-thick sections 
of paraffin-embedded tissues were utilized for immunohistochemi-
cal staining. Slide was deparaffinized, hydrated in ethyl alcohol and 
washed in tap water. Antigen retrieval was performed in 10 mmol/L 
sodium citrate buffer for 20 minutes using a Black & Decker vegetable 
steamer. Slides were blocked with 10% donkey serum for 30 minutes 
at room temperature and then washed using PBS. Primary antibodies 
for fibronectin, E-cadherin, α-SMA and Snail were diluted 1:100 with 
2% casein in bovine serum albumin, added to the slides and then in-
cubated overnight at 4°C. After washing, a secondary antibody was 
added for 20 minutes, and the slides were washed and incubated with 
a tertiary PAP complex for 20 minutes. Diaminobenzidine was added 
for 2 minutes and the slides were counterstained with haematoxy-
lin. A semi-quantitative score of staining intensity was determined by 
examining at least 5 fields of the peritoneum in each section under 
×400 magnification and with digital image analysis (MetaMorph ver-
sion 4.6r5, Universal Imaging Corp.). For Masson's trichrome staining, 
paraffin-embedded tissues processed in 5 µm-thick sections were 
deparaffinized, rehydrated in ethyl alcohol, washed in tap water and 
re-fixed in Bouin's solution for 1 hour at 56°C. After rinsing in run-
ning tap water for 10 minutes and staining with Weigert's iron hae-
matoxylin working solution for 10 minutes, the slides were stained 
with Biebrich scarlet-acid fuchsin solution for 15 minutes and washed 
in tap water. The sections were differentiated in phosphomolybdic-
phosphotungstic acid solution for 15 minutes, transferred to aniline 
blue solution and stained for 10 minutes. After rinsing briefly in tap 
water, the slides were reacted with 1% acetic acid solution for 5 min-
utes. The thickness of the peritoneum, which was defined as the tis-
sue between the mesothelial surface and the underlying muscle or 
parenchyma, was assessed as previously described.22
2.10 | Intravital fluorescence imaging
Female 5 week-age Balb/C nude mice for in vivo (n = 2/group) or ex 
vivo (n = 3) fluorescence imaging assay were fed with alfalfa-free 
diet after adaptation period. PTD-BMP (10 μg/100 μL) and rBMP 
(10 μg/100 μL) which was labelled with ICG were injected intra-peri-
toneally. In vivo intravital fluorescence imaging was taken immediately 
before and after PTD-BMP or rBMP injection, and measured by using 
VISQUE® InVivo Elite (Vieworks, Anyang, South Korea) under inhala-
tion anaesthesia by Isoflurane after 1, 2, 6, 24, 30, 48, 54, 72, 78 and 
168 hours later from initial injection. Ex vivo intravital fluorescence 
imaging of the mice skin and peritoneum was performed after 6 hours 
PTD-BMP injection by using VISQUE® InVivo Smart (Vieworks). All 
imaging data were analysed by CleVue™ software (Vieworks).
F I G U R E  1   Cytotoxicity of PTD-BMP-7 
in HPMCs. A, HPMCs were incubated 
for 72 h with TRP2. Cell viability was 
maintained at up to 104 ng/mL. ns, not 
significant vs Con. Data were presented as 
mean ± SE. Con, control
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2.11 | Statistical analysis
Statistical analyses were conducted by the SPSS software Ver. 21.0 
for Windows (SPSS, Inc). Data are expressed as mean ± standard 
errors of the mean (SEM). A one-way ANOVA with the Bonferonni 
multiple comparison test was used to analyse data. P < .05 was con-
sidered to be statistically significant.
3  | RESULTS
3.1 | Transduction of PTD-BMP-7 and secretion of 
BMP-7 in HPMCs
HPMCs remained viable up to 104 μg/mL of PTD-BMP-7 and incu-
bated for 24, 48 and 72 hours, which suggested that PTD-BMP-7 
F I G U R E  2   Transduction of PTD-BMP-7 and secretion of BMP-7 in HPMCs. A, HPMCs were transduced with 500 ng/mL of PTD-BMP-7 
and transduction of PTD-BMP-7 (red) was determined via confocal laser microscopy (×400). Nuclei are stained blue using 4′,6-diamidino-2-
phenylindole (DAPI). B, Transduction of PTD-BMP-7 into cells in a time-dependent manner. Total protein containing insoluble fraction and 
media were subjected to Western blot analysis to detect transduction of PTD-BMP-7 in HPMCs. C, HPMCs were treated with different 
doses of PTD-BMP-7 in FBS-free M199 media, FBS-free M199 media + PDF and PDF. The protein expression of the X press in the cell 
lysates increased in a PTD-BMP-7-dose-dependent manner. D, E, Secreted BMP-7 protein in FBS-free M199 media was successfully 
detected in a PTD-BMP-7-dose-dependent manner (E; Western blot, F; ELISA). *P < .01 vs PTD-BMP-7 0/Noggin +; **P < .001 vs PTD-
BMP-7 0/Noggin +. F, Schematic diagram for intracellular transduction of PTD-BMP-7 and secretion of mature BMP-7. Representative data 
from 4 individual experiments are shown. Data were presented as mean ± SE. Con, control; HPMCs, human peritoneal mesothelial cells; 
FBS, 10% foetal bovine serum; PDF, 4.25% peritoneal dialysis fluid
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F I G U R E  3   Effects of PTD-BMP-7 on EMT-related fibrosis in TGF-β1-treated HPMCs. HPMCs were incubated for 72 h with FBS-free 
M199 media (Con), PTD-BMP-7 (100 ng/mL), TGF-β1 (2 ng/mL) and TGF-β1 + PTD-BMP-7 (100 ng/mL). A, TGF-β1 significantly induced 
fibronectin, ColαI, α-SMA, and Snail mRNA expression and significantly reduced E-cadherin mRNA level in HPMCs when compared to 
control cells. These changes were significantly attenuated by PTD-BMP-7. *P < .001 vs Con; **P < .001 vs TGF-β1. B, Protein expressions 
of fibronectin, type I collagen, α-SMA, E-cadherin and Snail showed similar expression patterns to the mRNA expression in TGF-β1-treated 
HPMCs. Phospho-Smad 2/3 protein expression, which induced EMT, was also significantly higher in TGF-β1-treated HPMCs. However, the 
changes in TGF-β1-treated HPMCs were significantly abrogated by PTD-BMP-7. *P < .001 vs Con; P < .001 vs TGF-β1; #P < .01 vs. TGF-β1. 
Representative data from 3 individual experiments are shown. Data were presented as mean ± SE. Con, control; HPMCs, human peritoneal 
mesothelial cells; FBS, 10% foetal bovine serum; PDF, 4.25% peritoneal dialysis fluid
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did not exhibit cellular toxicity at that dose in HPMCs (Figure 1A). 
The immunofluorescence and Western blot analysis study dem-
onstrated the presence of PTD-BMP-7 in HPMCs (Figure 2A,B), 
indicating the successful delivery of PTD-BMP-7 into the cells. 
Western blot analysis also revealed that PTD-BMP-7 was suc-
cessfully delivered into the cells grown in FBS-free M199 culture 
media, M199 media + PDF and only PDF in a dose-dependent 
manner (Figure 2C). Next, we examined whether PTD-BMP-7 was 
adequately processed and BMP-7 was secreted in HPMCs. When 
we specifically added Noggin (4 μg/mL) as a BMP-7 receptor an-
tagonist, the secreted BMP-7 protein in the FBS-free M199 media 
was successfully detected based on the dosage of PTD-BMP-7 
(Figure 2D,E). These results indicated that the denatured, insoluble 
form of PTD-BMP-7 was successfully transduced into HPMCs and 
that the cells secreted soluble mature BMP-7 via intracellular pro-
cessing (Figure 2F).
3.2 | Effects of PTD-BMP-7 on TGF-β1-induced 
EMT in HPMCs
To evaluate the in vitro effects of PTD-BMP-7 on EMT, HPMCs 
were incubated for 72 hours with FBS-free M199 media (control), 
PTD-BMP-7 (100 ng/mL), TGF-β1 (2 ng/mL) and TGF-β1 + PTD-
BMP-7. The mRNA expression of E-cadherin was significantly lower 
(P < .001), whereas the mRNA expressions of fibronectin, colla-
gen type I α1 (ColαI), α-SMA and Snail were significantly higher in 
TGF-β1-treated HPMCs compared to control cells (P < .001). The 
F I G U R E  4   Effects of PTD-BMP-7 on peritoneal EMT-related fibrosis in PD rat models. A, The mRNA expression of E-cadherin was 
significantly lower, whereas the mRNA expressions of fibronectin, ColαI, α-SMA and Snail were significantly higher in rats treated with PDF 
when compared to control rats. These changes were significantly abrogated by PTD-BMP-7. *P < .001 vs Con; **P < .001 vs PD; #P < .05 
vs PD; †P < .01 vs PD. B, The protein levels of fibronectin, type I collagen, α-SMA, E-cadherin and Snail showed similar expression patterns 
to the mRNA expression in rats treated with PDF. Phospho-Smad 2/3 protein expression, which induced EMT, was also significantly higher 
in rats treated with PDF. However, these changes in rats treated with PDF were significantly abrogated by PTD-BMP-7. *P < .001 vs Con; 
**P < .001 vs PD. n = 6 per group. Data were presented as mean ± SE. Con, control; PDF, 4.25% peritoneal dialysis fluid
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changes in HPMCs exposed to TGF-β1 were significantly abrogated 
by PTD-BMP-7 treatment (Figure 3A). The protein expressions of 
E-cadherin, fibronectin, type I collagen, α-SMA and Snail showed a 
similar pattern to the mRNA expressions in TGF-β1-treated HPMCs 
(Figure 3B). Phospho-Smad 2/3 (p-Smad 2/3) protein expression, as 
a downstream signalling molecule of TGF-β1, was significantly higher 
in TGF-β1-treated HPMCs compared to control cells; however, PTD-
BMP-7 treatment reduced TGF-β1-induced Smad 2/3 phosphoryla-
tion in HPMCs (Figure 3B).
3.3 | Effects of PTD-BMP-7 on the development of 
peritoneal EMT-related fibrosis
The effects of PTD-BMP-7 on peritoneal EMT-related fibrosis were 
explored in PDF-induced PD fibrosis rat models. The mRNA expres-
sion of E-cadherin was significantly lower (P < .001), whereas the 
mRNA expressions of fibronectin, ColαI, α-SMA and Snail were sig-
nificantly higher in rats treated with PDF compared to control rats 
(P < .001). These changes were significantly abrogated by PTD-BMP-7 
(Figure 4A). The protein expressions of E-cadherin, fibronectin, type 
I collagen, α-SMA and Snail showed similar patterns to the mRNA 
expression in rats treated with PDF. PTD-BMP-7 normalized the in-
crease in PDF-induced EMT-related protein expressions (Figure 4B). 
Furthermore, p-Smad 2/3 protein expression was also significantly 
higher in PD rats compared to that of control rats. However, the p-
Smad 2/3 protein expression in PD rats was ameliorated by PTD-
BMP-7 treatment (Figure 4B). Immunohistochemical analysis of the 
peritoneum also revealed that the expressions of α-SMA, Snail and fi-
bronectin were significantly higher in rats treated with PDF compared 
to control rats, and PTD-BMP-7 significantly abrogated the PDF-
induced fibrosis in PD rats (Figure 5A). In addition, Masson's trichrome 
staining demonstrated that the sub-mesothelial layer and peritoneal 
fibrosis were significantly more increased in PD rats treated with PDF 
compared to control rats. These changes were significantly improved 
by PTD-BMP-7 treatment (Figure 5A). In addition, we found that PTD-
BMP-7 treatment was effective for prevention of PDF-induced peri-
toneal fibrosis in a dose-dependent manner (Figure 5B).
3.4 | Effects of PTD-BMP-7 on established 
peritoneal fibrosis
Next, we evaluated the effects of PTD-BMP-7 on established peri-
toneal fibrosis in 6-week PD rat models. After peritoneal fibrosis 
had developed by treating PDF during 2 weeks period, PTD-BMP-7 
was treated for subsequent 4 weeks. The mRNA expression of 
E-cadherin was significantly lower, whereas mRNA expressions 
of fibronectin, ColαI, α-SMA, and Snail were significantly higher 
in rats treated with PDF for 6 weeks when compared to control 
rats (P < .001). These changes were significantly abrogated even 
after delayed administration of PTD-BMP-7 (Figure 6A). The pro-
tein expressions related to EMT and fibrosis, that is E-cadherin, 
fibronectin, type I collagen, α-SMA and Snail were activated in 
6-week PD rat models, which were improved after PTD-BMP-7 
administration. These EMT and fibrosis induced by PDF were 
partially recovered in rats subjected to the delayed PTD-BMP-7 
treatment (Figure 6B). Immunohistochemical staining of fibronec-
tin and Masson's trichrome staining also showed protective and 
improving anti-fibrotic effect of PTD-BMP-7 in 6-week PD rat 
models (Figure 6C). Of note, to evaluate the effects of PTD-BMP-7 
on progressively established peritoneal fibrosis, PTD-BMP-7 was 
treated after 2 weeks of PDF treatment in 6-week PD rat models. 
The mRNA and protein expression of E-cadherin were significantly 
lower, whereas mRNA and protein expressions of fibronectin, type 
I collagen, α-SMA and Snail were significantly higher in rats treated 
with PDF for 6 weeks when compared to control rats. These 
changes were significantly abrogated by PTD-BMP-7 administered 
after 2 weeks of PDF treatment. (Figure 6A,B). Masson's trichrome 
staining also showed anti-fibrotic effect of PTD-BMP-7 on pro-
gressively established peritoneal fibrosis in 6-week PD rat models 
(Figure 6C).
3.5 | Comparison of the anti-fibrotic effects of 
rBMP-7 and PTD-BMP-7
To confirm the effectiveness of PTD-BMP-7, the effects of 
rBMP-7 and PTD-BMP-7 on peritoneal EMT-related fibrosis were 
compared by same dosage. The mRNA and protein expression of 
E-cadherin were significantly lower, whereas the mRNA and pro-
tein expressions of fibronectin, type I collagen, α-SMA and Snail 
were significantly higher in rats treated with PDF when compared 
to control rats. These changes were significantly abrogated after 
administration of PTD-BMP-7, however, weekly administration 
of rBMP-7 did not improve the PDF-induced EMT-related peri-
toneal fibrosis (Figure 7A,B). Masson's trichrome staining also 
showed that only PTD-BMP-7 had anti-fibrotic effect in PD rat 
models (Figure 7C). In addition, to evaluate a progressive release 
of PTD-BMP7, in vivo and ex vivo experiments were conducted. 
F I G U R E  5   Masson's trichrome staining and immunohistochemical staining of the peritoneum in PD rat models. A, Peritoneal fibrosis 
assessed via Masson's trichrome staining was found to be significantly more extensive in PD rats than in control rats, and these changes 
were significantly attenuated by PTD-BMP-7. The intensity of E-cadherin staining was significantly lower, whereas fibronectin, α-SMA and 
Snail staining intensities were significantly higher in PD rats when compared to control rats. PTD-BMP-7 significantly ameliorated these 
changes in PD rats (×100). *P < .001 vs Con; **P < .001 vs PD; #P < .01 vs PD. B, PTD-BMP-7 treatment was effective for prevention of 
PDF-induced peritoneal fibrosis in a dose-dependent manner in 4-weeks PD rat models. *P < .001 vs Con; **P < .001 vs PD; #P < .01 vs PD. 
n = 6 per group. Data were presented as mean ± SE. Scale bar = 200 µm. Con, control; PDF, 4.25% peritoneal dialysis fluid
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F I G U R E  6   Effects of PTD-BMP-7 on established peritoneal fibrosis in 6-wk PD rat models. A, The mRNA expression of E-cadherin was 
significantly lower, whereas the mRNA expressions of fibronectin, ColαI, α-SMA and Snail were significantly higher in rats treated with 
PDF when compared to control rats. These changes were significantly abrogated by PTD-BMP-7 administered 2 wk later. *P < .001 vs Con; 
**P < .001 vs PD; #P < .01 vs PD; †P < .05 vs PD. B, The protein levels of fibronectin, type I collagen, α-SMA, E-cadherin and Snail showed 
similar expression patterns to the mRNA expression. Phospho-Smad 2/3 protein expression, which induced EMT, was also significantly 
higher in rats treated with PDF. However, the changes in rats treated with PDF were significantly abrogated by PTD-BMP-7 administered 
2 wk later. *P < .001 vs Con; **P < .001 vs PD; #P < .05 vs PD. n = 6 per group. Data were presented as mean ± SE. Con, control; PDF, 4.25% 
peritoneal dialysis fluid. C, Peritoneal fibrosis assessed via Masson's trichrome staining was found to be significantly more extensive in PD 
rats treated with 4.25% PDF than in control rats. These changes were significantly attenuated by PTD-BMP-7 administered 2 wk later. The 
intensity of E-cadherin staining was significantly lower, whereas fibronectin, α-SMA and Snail staining intensities were significantly higher 
in PD rats when compared to control rats. PTD-BMP-7, administered 2 wk later, significantly ameliorated these changes in PD rats (×100). 
*P < .001 vs Con; **P < .001 vs PD; # P < .05 vs PD; †P < .01 vs PD. n = 6 per group. Data were presented as mean ± SE. Scale bar = 200 µm. 
Con, control; PDF, 4.25% peritoneal dialysis fluid
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Compared to rBMP-7, PTD-BMP-7 showed longer half-life and big-
ger area under the curve which was calculated over the 1 week 
from the initial injection (Figure 7D). Of note, PTD-BMP-7 that 
was absorbed and maintained on the peritoneum membraned 
could be observed obviously. (Figure 7E).
4  | DISCUSSION
In the present study, PTD-BMP-7, an indirect prodrug delivery system 
of BMP-7, was shown to effectively block peritoneal membrane dam-
age in in vitro and in vivo PD models. PTD-BMP-7 also partially de-
layed the progression of established PDF-induced peritoneal fibrosis.
Long-term exposure of the peritoneal membrane to glucose and 
non-physiologic PDF induces peritoneal inflammation, thereby un-
dergoing peritoneal fibrosis, which eventually leads to ultrafiltration 
failure.23 Although resident stromal fibroblasts have been recog-
nized as the main origin of the myofibroblasts that cause these peri-
toneal membrane changes,24 recent studies have shown PMC EMT 
to also play an important role in these changes.23,25,26 EMT is a com-
plicated process that includes the loss of cell polarity, loss of cell-
cell adhesion and acquisition of migration and invasive properties. 
This process induces PMCs to become myofibroblast-like cells.27 
Thus, PMCs that have undergone EMT invade the sub-epithelial 
stroma and produce extracellular matrix (ECM) components, such 
as fibronectin and ColαI, which finally lead to peritoneal membrane 
F I G U R E  6   (Continued)
13518  |     KIM et al.
F I G U R E  7   Comparison of the effects of rBMP-7 and PTD-BMP-7. A, The mRNA expression of E-cadherin was significantly lower, whereas 
the mRNA expressions of fibronectin, ColαI, α-SMA and Snail were significantly higher in rats treated with PDF when compared to control rats. 
These changes were significantly abrogated only after administration of PTD-BMP-7. *P < .001 vs Con; **P < .001 vs PD. B, The protein levels 
of fibronectin, type I collagen, α-SMA, E-cadherin and Snail showed similar expression patterns to the mRNA expression in rats treated with 
PDF. Phospho-Smad 2/3 protein expression, which induced EMT, was also significantly higher in rats treated with PDF. However, these changes 
in rats treated with PDF were significantly abrogated by only PTD-BMP-7. *P < .001 vs Con; **P < .001 vs PD. n = 6 per group. Data were 
presented as mean ± SE. Con, control; PDF, 4.25% peritoneal dialysis fluid. C, Peritoneal fibrosis assessed via Masson's trichrome staining was 
found to be significantly more extensive in PD rats treated with 4.25% PDF than in control rats. These changes were significantly attenuated 
by only PTD-BMP-7 administered. D, Monitoring by intravital in vivo fluorescence imaging, results of biodistribution showed that PTD-BMP-7 
was more stably sustained than rBMP-7. About 5 times longer half-life was shown at PTD-BMP-7 (56.439 h) than rBMP-7 (10.495 h), and about 
9 time more area under the curve was shown at PTD-BMP-7 (9.861) compared with rBMP-7 (1.000) in Balb/c nude mice. E, Monitoring by ex 
vivo fluorescence imaging, after 6 h from intra-peritoneal injection of the ICG labelled PTD-BMP, ICG signal was detected at skin and peritoneal 
membrane tissue on ex-vivo fluorescence imaging. 18.5 (±8.289) % was delivered. Total signal intensity ({[p/s/cm2/sr]/[µW/cm2]} × cm2) of 
every time point was normalized by subtraction of background signal at 0 h (before injection). *P < .001 vs Con; **P < .001 vs PD. n = 6 per 
group. Data were presented as mean ± SE. Scale bar = 200 µm. Con, control; PDF, 4.25% peritoneal dialysis fluid
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fibrosis.2 It should be noted that a hyperglycaemic condition stabi-
lizes and activates Snail via O-GlcNAc, resulting in EMT.28
In the present study, TGF-β1 treatment significantly decreased 
E-cadherin expression and clearly increased α-SMA and Snail ex-
pressions, accompanied by a significant increase in fibronectin 
expression in cultured HPMCs. A similar finding was also found in 
the peritoneal tissues of PD rats. The profibrotic cytokine, TGF-β1, 
plays major roles to induce peritoneal EMT and fibrosis in patients 
undergoing PD.29 TGF-β1 activates downstream Smad 2/3 cascades, 
which consequently results in molecular transition, down-regulating 
intracellular adhesion molecules such as E-cadherin and ZO-1 and 
up-regulating mesenchymal molecules such as α-SMA, Snail and 
fibronectin.2,29 However, the effect of TGF-β1 on various physio-
logic functions related to cell survival, should not be overlooked.30 
Attempting to inhibit TGF-β1 for preventing organ fibrosis arising 
from chronic state of various disease31 may block numerous criti-
cal downstream signalling pathways in regard to cell survival.29 
Therefore, the clinical use of TGF-β1-inhibiting therapy has been 
limited. On the other hand, BMP-7 is an endogenous protein that 
antagonizes TGF-β1 and reverses organ fibrosis caused by chronic 
state of various disease.32-35 In controlling EMT and fibrosis, a del-
icate balance between TGF-β1 and BMP-7 is maintained.36 They 
bind to specific type I serine-threonine kinase receptors and induce 
distinct intracellular signals via the Smad-dependent pathway.7-9 
Particularly, BMP-7 inhibits the activation of both, the Smad 2/3-de-
pendent and Smad-independent pathways, via the activation of 
Smad 1/5/8.37-39 Interestingly, Lourerio et al showed that exogenous 
rhBMP-7 completely inhibits the TGF-β1-induced EMT of HPMCs in 
vitro and ameliorates peritoneal fibrosis in PD rat models.3 However, 
it is difficult to apply exogenous rhBMP-7 into clinical practices be-
cause of the short biological half-life of rhBMP, brought about by 
fast enzymatic degradation.10,11 Furthermore, soluble rhBMP-7 can-
not be applied in hypertonic conditions because the hydrogen bond 
in the tertiary structures of growth factors is easily destroyed by pH 
or osmotic pressure.40 By solving the structural problems of recom-
binant proteins, they can be expected to demonstrate clinical value 
as therapeutic agents. The present study suggests that binding PTD 
without specific carriers, like those in viral transfections, increases 
efficiency and overcomes structural problems of rhBMP-7.
The eukaryotic cell membrane consists of a lipid bilayer with 
embedded proteins. Normally, most peptides and proteins cannot 
across the cell membrane because of the hydrophobicity of these 
lipids. However, the discovery of several PTDs, also known as 
cell-penetration proteins (CPPs) made an interesting exception to 
this rule.41 Until now, various types of CPPs have been identified 
such as Antennapedia (Antp), herpes simplex virus type 1 (HSV-1) 
protein VP22, HIV-derived cationic TAT, transportan and polyargi-
nine sequences (Arg8).42 TAT peptides, in particular, are predom-
inantly a type of CPP, with a distinguished ability to across the 
eukaryotic cell membrane, that are used to deliver peptides and 
proteins into cells.43 This ability of the TAT peptides to be used as 
intracellular delivery of large molecules has received much interest 
since Frankel and Pabo 13 discovered that HIV-derived cationic 
TAT could enter cells. The first proof-of-concept of the in vivo 
application of PTD in delivering small peptides and large proteins 
was reported by Dowdy's group.17 Protein transduction involves a 
three-step process: (a) binding of PTD to the cellular membrane, 
(b) cellular uptake by endocytosis and (c) endosome-to-cytosol 
transport. Although the precise mechanism of endosome-to-cy-
tosol transport is not clear yet, pH drop in maturing endosomes is 
thought to be crucial elements.14
Recently, we developed a PTD-based rBMP-2 polypeptide (PTD-
BMP-2) to delivery polypeptides into cells, followed by furin-medi-
ated protein cleavage and secretion of active growth factors from 
the cells.12 The study demonstrated an indirect delivery system 
using a PTD-protein, thereby mimicking endogenous protein bio-
genesis. As a denatured polypeptide, the prodrug was also resistant 
to proteolytic degradation via body fluids. In fact, PTD-BMP-2 was 
functional during in vivo bone regeneration, with only a few micro-
grams being sufficient for the process.12 In line with these findings, 
the PTD-BMP-7 dosage (10 μg/wk) instilled intra-peritoneally in 
the present study was significantly smaller when compared to the 
rBMP-7 dosage (100-300 μg/kg/d) used to treat peritoneal fibrosis 
in PD rat models in other studies.3,32 An EMT-suppressing effect was 
observed with the PTD-BMP-7 dose used in this study. Moreover, 
we also showed that early or late PTD-BMP-7 treatments reduced 
EMT and confirmed the effect of PTD-BMP-7 on established perito-
neal fibrosis. Therefore, the results of the present study suggested 
that PTD-BMP-7 effectively blocked peritoneal membrane damage 
in PD rat models.
In summary, PTD-BMP-7 significantly blocked TGF-β1-induced 
EMT of HPMCs. Moreover, low PTD-BMP-7 doses significantly 
ameliorated this PD-induced peritoneal fibrosis in animal models. 
These findings suggest that PTD-BMP-7 treatment is considered 
to be an effective treatment modality for peritoneal fibrosis in PD 
patients.
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